Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone know why sqnm is going crazy today? up .48(16%) Its been dormant since the test problems.
anyone know whats up today? shooting up like crazy!! up .48 (16%)
Picked up some more here at these levels. I agree, this should make alot of people alot of money in the coming months.
I wasnt watching close enough and it hit my sell at .16. Have watched this a long time, and im hoping as well it continues its trends and moves back down again to get back in. We shall see, eventually it will stop getting back down around .10, which will be ok, as long as im back in when it does.
Ken, are you from Ohio? What Part. I live in North Canton. Glad to meet another Buckeye!!
why not just post it in english then? save us all the hassle
Should be getting a good pump and dump any time with this one! Another great small cap soc. featured pick!! lol
Should be getting close for another massive pump and dump for this POS!! Maybe we can recoup some of the massive losses. Wish I could have watched the pps everyday, all day, and maybe I could have sold for a small loss, compared to the hefty one alot of us have just so others could make some money at our expense. Stay away from any featured stocks at Small Cap Society, IMO. They only care about a select few of their people, and use the rest of us to make money for themselves!
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distributionhttp://ih.advfn.com/p.php?pid=nmona&cb=1258640162&article=40433941&symbol=NB%5ENPHC
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today the introduction of Nyloxin OTC for the treatment of chronic pain. Nyloxin OTC will be marketed and sold internationally alongside the Company’s prescription pain reliever, Nyloxin Rx.
“Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States” explained Dr. Paul Reid, CEO of ReceptoPharm. “By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC,” he added.
Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The Company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.
“The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. “With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market,” he concluded.
Nyloxin OTC, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Nyloxin.com
where did u see that information. It could be a real boost for PWRM. Thanks
CAN SOMEONE POST A LEVEL 2 SCREENSHOT FOR ME. THANKS! sorry for the caps
alot of shares moving at 10 1/2 cents. almost 6 1/2 mill traded already
Ken, take a look at PWRM. Up 38% today, and they start a conference tomorrow. Just an FYI!
Dont forget about the upcoming session in China.
HOUSTON--(BUSINESS WIRE)--Power3 Medical Products, Inc. (OTCBB: PWRM - News), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf, will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of Personalized Medicine.”
Heres the entire article:
http://finance.yahoo.com/news/Power3-Medical-Products-Inc-bw-1324768701.html?x=0&.v=1
i play on ultimate bet,full tilt,power poker club, and sometimes bodog
you are welcome sir, glad to help any way I can
can u post this one on sheffs site. i cant cuz im not a paying member.
lol, same here. watching the market and playing some poker
what if we kept the 2 separate ones and just had everyone vote for both. It could give us more attention, and just might get them to look at it?
where did everybody go? did someone die here, or just napping? awful quiet
anything can help, gotta get the word out there
ok, its done
NPHC info:
XenaCare Holdings Announces Availability of Cobroxin Through the Chain Drug Marketing Association
XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. CDMA currently communicates with over 135 buying headquarters that total over 6,000 outlets in 32 states.
“As one of the largest pharmacy organizations in the United States, we are excited to be working with CDMA to distribute Cobroxin to its independent pharmacy members,” explained Frank Rizzo, President of XenaCare Holdings. “Having a presence with CDMA will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign,” he concluded.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
· All Natural
· Non-Addictive
· Non-Narcotic
· Non-Opiate
· More Potent than Morphine
· Long Lasting
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced in October that it had begun accepting orders for Cobroxin online at Cobroxin.com. Additionally, the Company has recently begun distribution to online and brick-and-mortar retailers and will continue to announce locations where Cobroxin will be available for sale.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. XenaCare’s clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.XenaCareHoldings.com
http://www.Cobroxin.com
Cautionary Note Concerning Forward Looking Statements
Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans to introduce Cobroxin into the commercial marketplace and for additional marketing campaigns are forward looking statements. Although these forward looking statements constitute our current plans, the timing, marketing channels and advertising support for the product may change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.
Cant see why this shouldnt be at least 1.00 right now. There are plenty of crappy co.'s out there with no products to market yet, that are trading higher than this.If its the combo of MM's and shorts, 1 healthy pr on sales could double or triple the pps in a flash. JMHO, but anyone have an opinion on it?
cant figure this stock out, up, down, up, down.
9.16 million traded in 1st hour. Time to put the big squeezee on!
no problem, it can only help get national recognition for the product!
nice movement premarket, 1.31
News is out!!
EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application for Review
Marketing Application Also Accepted in Israel
TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene(R) (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. Health Canada's performance target for the completion of review and a decision is within 300 days.
"We are pleased to have completed another key milestone in our North American regulatory strategy for Ceplene(R)," stated Jack Talley, President and Chief Executive Officer of EpiCept. "As the next step in this process, we are focused on the filing of a New Drug Application for Ceplene(R) with the U.S. Food and Drug Administration for AML remission maintenance. As previously stated, we intend to utilize the approval of Ceplene(R) in order to establish a fully integrated specialty pharmaceutical company focused in hematology in North America."
EpiCept also announced today that Israel's Ministry of Health has accepted a marketing application for Ceplene(R) for the remission maintenance of AML patients in first remission. The Company's distribution and marketing partner for Ceplene(R) in Israel, Megapharm Ltd., filed the application and will market Ceplene(R) upon approval. A decision on this application is anticipated late next year.
Ceplene(R) is approved in the European Union for the remission maintenance and prevention of relapse in patients with AML in first remission. The company is continuing negotiations with prospective partners for the European marketing rights to Ceplene(R). In June 2009 EpiCept launched a named patient program for Ceplene(R) in partnership with IDIS under which physicians in all major global markets excluding the U.S. can prescribe Ceplene(R).
Awhile back I suggested we all go to the doctors site to register and vote for a show on cobroxin. Have you or one of the other moderators put the link in the ibox? We need to get as many votes and comments we can. I only saw 49 comments, unless some are going to another cobroxin topic in there. As of tonight we are number 1 under alternative medicine with 1530 points:
Vote
1530
Points
Cobroxin Using Cobra Venom for the Treatment of Chronic Pain
Posted by cobroxin to Alternative Medicine, Oct 16, 2009 7:17pm
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain,...
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
* All Natural
* Non-Addictive
* Non-Narcotic
* Non-Opiate
* More Potent than Morphine
* Long Lasting
Cobroxin offers a novel mechanism of action from its active pharmaceutical ingredient, Asian cobra venom.
im averaged in, so i was glad to see the rise, but im in for the longer haul. So much down the line, as long as they arent involved with madoff, or some other illegal thing, they will be making me alot of money one day in the not too distant future!
Just checked out the slide presentation from today. Very Interesting, and looks like they have alot on their plate, which is good for us investors. GLA Heres a link to the slideshow:
http://files.shareholder.com/downloads/EPCT/764325409x0x329032/fc022322-6187-4cbc-80c0-d7c8a94cf770/EpiCept%20Bio%20Europe%20Corporate%20Presentation%2011%2009.pdf
Its not about day trading this one. I think, its jmho, that he was referring to the fact that its a steal at 1.40. Have been with this one since it was .90, and the daily fluctuation usually not that great of a spread to day trade if u plan on getting in and out on the same day. Seems to go up to about 2.00 or so, then slowly back down to around this range, then slowly back up. Would say be careful if you want in and out quick! IMO
Guess everyone lost interest in this one today!
wondering if news leaked about the facility or the h1n1. Would think the h1n1 news would be a bigger pop, but thats just my opinion.
wondering the same
This hit my email a little while ago:
http://www.twst.com/pdf/ANG600.pdf
Not sure if someone else may have posted it today. Pretty good stuff!
Been quiet here. Who in their right mind would sell at .04? Must be pretty desperate!!